IRON Stock: Price, Earnings History and SEC Filings
Disc Medicine, Inc. (IRON) last traded at $80.84, down 2.41% on the latest session and up 23.5% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-1.54 against an analyst estimate of $-1.58, a beat of 2.5%.
$80.84 -2.41%
1 month+23.50%
52-week high$99.50
52-week low$40.00
Volume684,975
ExchangeNasdaqGM
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
IRON earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Jul 30, 2026 | $-1.54 | $-1.58 | +2.53% |
| Mar 2026 | May 5, 2026 | $-1.65 | $-1.55 | -6.45% |
| Dec 2025 | Feb 26, 2026 | $-1.62 | $-1.69 | +4.14% |
| Sep 2025 | Nov 6, 2025 | $-1.77 | $-1.48 | -19.59% |
IRON beat the analyst EPS estimate in 2 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for IRON
SEC filing data is not available right now. You can search for IRON on SEC EDGAR.
IRON news
- Disc Medicine Delivers Promise For Patients with Sunlight Sensitivity In Successful Pivotal StudyOct 22, 2026 · finance.yahoo.com
- Disc Medicine Announces Pricing of $450 Million Upsized Public Offering of Common StockOct 21, 2026 · finance.yahoo.com
- A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on MondayOct 20, 2026 · finance.yahoo.com
- Disc Medicine Stock Jumps After Phase 3 Trial Success And FDA Refiling PlanOct 20, 2026 · finance.yahoo.com
- Disc Medicine (IRON) APOLLO Win Puts Its Valuation Discount Back In FocusOct 19, 2026 · finance.yahoo.com
- Disc Medicine Announces Proposed $350 Million Public Offering of Common Stock and Pre-Funded WarrantsOct 19, 2026 · finance.yahoo.com
- What Could Disc Medicine (IRON) Reveal From Its Phase 3 APOLLO Trial?Oct 19, 2026 · finance.yahoo.com
- Disc’s once-spurned rare disease drug to get a second chance at approvalOct 19, 2026 · biopharmadive.com
About Disc Medicine, Inc.
Disc Medicine, Inc. (IRON) is a US-listed public company on Nasdaq.